AstraZeneca’s LATIFY Lung Cancer Trial of Ceralasertib–Imfinzi Combo Misses Survival Goal

AstraZeneca ( (GB:AZN) ) has issued an update.

AstraZeneca reported that its Phase III LATIFY trial testing the ATR inhibitor ceralasertib in combination with its immunotherapy Imfinzi in patients with previously treated, locally advanced or metastatic non-small cell lung cancer failed to meet its primary endpoint of improving overall survival compared with standard chemotherapy agent docetaxel. The company said the combination was generally well tolerated with no new safety signals and confirmed that full data will be shared at an upcoming medical meeting, underscoring both the challenges of extending immunotherapy benefits in heavily pre-treated lung cancer patients and AstraZeneca’s continued strategic emphasis on novel oncology combinations despite this setback.

The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic expansions and product approvals further enhance its outlook. However, the high valuation and moderate technical indicators slightly temper the overall score.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focused on the discovery, development and commercialisation of prescription medicines across Oncology, Rare Diseases and BioPharmaceuticals, including cardiovascular, renal and metabolic, and respiratory and immunology therapies. Its extensive oncology and immuno-oncology portfolios, which include the checkpoint inhibitor Imfinzi, position the group as a leading player in cancer care, with products sold in more than 125 countries and used by millions of patients worldwide.

Average Trading Volume: 2,249,463

Technical Sentiment Signal: Strong Buy

Current Market Cap: £212B

Learn more about AZN stock on TipRanks’ Stock Analysis page.